Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIV-CAR-T for Functional Cure in HIV-1/AIDS Patients
NCT06880380Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HIV-CAR-T in human immunodeficiency virus infection (HIV), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Incidence of adverse reactions at 12 weeks. Started Sep 2025; status: recruiting.
02
Drugs
HIV-CAR-T
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06880380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06880380.